Tags

Type your tag names separated by a space and hit enter

Medical management of lower urinary tract symptoms in men with benign prostatic enlargement.
Adv Ther. 2013 Apr; 30(4):309-19.AT

Abstract

With the high prevalence of bothersome lower urinary tract symptoms (LUTS) in older men, clinical management has to be fairly simple and straightforward. In the absence of severe problems requiring immediate action, and after excluding possible other etiological factors by a simple diagnostic algorithm, the key parameter for therapeutic decisions is the severity of LUTS, in particular the degree of annoyance and irritation, and prostatic enlargement. Patients with bothersome LUTS request rapid improvement but also worry about possible deterioration, complications, and the need for surgery. With a prostate volume above 30-40 mL and/or prostate-specific antigen (PSA) serum >1.5 ng/mL, the combination of an alpha-1 blocker with a 5-alpha-reductase inhibitor (5-ARI) should be first-line treatment. With prostates <30 mL at baseline the issue whether the prostate really is the culprit becomes central. Given the rapid onset of action of alpha-1 blockers, a 4-6-week trial appears to be a logical approach. If the International Prostate Symptom Score does not improve and storage symptoms prevail, an overactive bladder appears more likely as causative factor and antimuscarinics are the next step. Based on available data this is recommended as add-on medication to the alpha-1 blocker. With no improvement, or increasing postvoid residual the diagnostic algorithm needs to be revisited and more extensive urodynamic evaluation may be needed.

Authors+Show Affiliations

Department of Urology, Medical University Vienna, Waehringer Guertel, Vienna, Austria. Michael.marberger@A1.net

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

23584673

Citation

Marberger, Michael. "Medical Management of Lower Urinary Tract Symptoms in Men With Benign Prostatic Enlargement." Advances in Therapy, vol. 30, no. 4, 2013, pp. 309-19.
Marberger M. Medical management of lower urinary tract symptoms in men with benign prostatic enlargement. Adv Ther. 2013;30(4):309-19.
Marberger, M. (2013). Medical management of lower urinary tract symptoms in men with benign prostatic enlargement. Advances in Therapy, 30(4), 309-19. https://doi.org/10.1007/s12325-013-0022-7
Marberger M. Medical Management of Lower Urinary Tract Symptoms in Men With Benign Prostatic Enlargement. Adv Ther. 2013;30(4):309-19. PubMed PMID: 23584673.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Medical management of lower urinary tract symptoms in men with benign prostatic enlargement. A1 - Marberger,Michael, Y1 - 2013/04/12/ PY - 2013/02/18/received PY - 2013/4/16/entrez PY - 2013/4/16/pubmed PY - 2014/1/22/medline SP - 309 EP - 19 JF - Advances in therapy JO - Adv Ther VL - 30 IS - 4 N2 - With the high prevalence of bothersome lower urinary tract symptoms (LUTS) in older men, clinical management has to be fairly simple and straightforward. In the absence of severe problems requiring immediate action, and after excluding possible other etiological factors by a simple diagnostic algorithm, the key parameter for therapeutic decisions is the severity of LUTS, in particular the degree of annoyance and irritation, and prostatic enlargement. Patients with bothersome LUTS request rapid improvement but also worry about possible deterioration, complications, and the need for surgery. With a prostate volume above 30-40 mL and/or prostate-specific antigen (PSA) serum >1.5 ng/mL, the combination of an alpha-1 blocker with a 5-alpha-reductase inhibitor (5-ARI) should be first-line treatment. With prostates <30 mL at baseline the issue whether the prostate really is the culprit becomes central. Given the rapid onset of action of alpha-1 blockers, a 4-6-week trial appears to be a logical approach. If the International Prostate Symptom Score does not improve and storage symptoms prevail, an overactive bladder appears more likely as causative factor and antimuscarinics are the next step. Based on available data this is recommended as add-on medication to the alpha-1 blocker. With no improvement, or increasing postvoid residual the diagnostic algorithm needs to be revisited and more extensive urodynamic evaluation may be needed. SN - 1865-8652 UR - https://www.unboundmedicine.com/medline/citation/23584673/Medical_management_of_lower_urinary_tract_symptoms_in_men_with_benign_prostatic_enlargement_ L2 - https://dx.doi.org/10.1007/s12325-013-0022-7 DB - PRIME DP - Unbound Medicine ER -